LENZ - NASDAQ

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.13

-0.14%

HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$223.56M

EPS-2.8500

P/E Ratio-5.61

Earnings Date07/29/2026

LENZ

Preferred Stock

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Failed to load chart data

LENZ Therapeutics, Inc. Competitors Analysis of preferred-stock

LENZ · NASDAQ

Company	preferred-stock	CAGR 3Y	CAGR 5Y	CAGR 10Y
No comparison data available We couldn't find preferred-stock data for this stock's competitors.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.13, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $7.13

Related Guides

Blog Categories

Continue your LENZ research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.